A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review.
JAK/STAT
RET inhibitor
case report
infection
pralsetinib
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2024
2024
Historique:
received:
20
03
2024
accepted:
08
07
2024
medline:
14
8
2024
pubmed:
14
8
2024
entrez:
14
8
2024
Statut:
epublish
Résumé
Selective rearranged during transfection (RET) tyrosine kinase inhibitor, pralsetinib, demonstrated clinical efficacy and was well tolerated in lung and thyroid cancers with
Identifiants
pubmed: 39139787
doi: 10.3389/fmed.2024.1402902
pmc: PMC11319124
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
1402902Informations de copyright
Copyright © 2024 Poumeaud, Jaffrelot, Gomez-Roca, Korakis, Leonardi, Joly, Mazières, Guimbaud, Fares and Alouani.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.